Literature DB >> 11427273

Optimization of DNA immunization against human cytomegalovirus.

V Endrész1, K Burián, K Berencsi, Z Gyulai, L Kari, H Horton, D Virok, C Méric, S A Plotkin, E Gönczöl.   

Abstract

The immune responses of mice injected with plasmids VR-gB and VR-gB Delta tm expressing the full-length membrane-anchored, or secreted forms of human cytomegalovirus (HCMV)-glycoprotein B (gB), respectively, and VR-pp65 expressing the HCMV-phosphoprotein 65 (pp65) were analyzed. Pretreatment of mice with the local anesthetic bupivacaine did not enhance antibody production, and IFN-alpha co-expressed with the immunizing plasmids induced a moderate increase in the antibody response. However, antibody response was higher in mice inoculated at three sites in the musculus quadriceps than in mice inoculated at one site with the same dose and in the same muscle. pVR-gB Delta tm induced significantly higher antibody titers than the construct expressing the membrane-anchored form of gB, and priming with pVR-gB Delta tm followed by boosting with the gB subunit resulted in high-titer antibody responses. Immunization with VR-pp65 induced dose-dependent CTL responses in about 50% of the mice at a dose of 50 microg. Co-expression of IFN-alpha did not affect the number of responding mice. These findings might be important for optimization of humoral and cellular immune responses to HCMV after DNA vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427273     DOI: 10.1016/s0264-410x(01)00116-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

3.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 5.  Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Authors:  Maria Grazia Revello; Giuseppe Gerna
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

6.  Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.

Authors:  Zhongde Wang; Corinna La Rosa; Rebecca Maas; Heang Ly; John Brewer; Shahram Mekhoubad; Pirouz Daftarian; Jeff Longmate; William J Britt; Don J Diamond
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.

Authors:  Felix Wussow; Flavia Chiuppesi; Joy Martinez; John Campo; Erica Johnson; Christin Flechsig; Maegan Newell; Elaine Tran; Jose Ortiz; Corinna La Rosa; Andreas Herrmann; Jeff Longmate; Rana Chakraborty; Peter A Barry; Don J Diamond
Journal:  PLoS Pathog       Date:  2014-11-20       Impact factor: 6.823

8.  Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice.

Authors:  Taylor Pursell; Jennifer L Spencer Clinton; Jie Tan; Rongsheng Peng; Paul D Ling
Journal:  PLoS One       Date:  2022-03-21       Impact factor: 3.240

9.  Characteristics of oligodeoxyribonucleotides that induce interferon (IFN)-alpha in the pig and the phenotype of the IFN-alpha producing cells.

Authors:  Kristina Domeika; Mattias Magnusson; Maija-Leena Eloranta; Lisbeth Fuxler; Gunnar V Alm; Caroline Fossum
Journal:  Vet Immunol Immunopathol       Date:  2004-09       Impact factor: 2.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.